315 related articles for article (PubMed ID: 38338854)
21. Imaging of Tumor Metabolism Using Positron Emission Tomography (PET).
Apostolova I; Wedel F; Brenner W
Recent Results Cancer Res; 2016; 207():177-205. PubMed ID: 27557539
[TBL] [Abstract][Full Text] [Related]
22. Prospective Comparison of 99mTc-MDP Scintigraphy, Combined 18F-NaF and 18F-FDG PET/CT, and Whole-Body MRI in Patients with Breast and Prostate Cancer.
Minamimoto R; Loening A; Jamali M; Barkhodari A; Mosci C; Jackson T; Obara P; Taviani V; Gambhir SS; Vasanawala S; Iagaru A
J Nucl Med; 2015 Dec; 56(12):1862-8. PubMed ID: 26405167
[TBL] [Abstract][Full Text] [Related]
23. PET Imaging for Breast Cancer.
Fowler AM; Cho SY
Radiol Clin North Am; 2021 Sep; 59(5):725-735. PubMed ID: 34392915
[TBL] [Abstract][Full Text] [Related]
24. Response to therapy in breast cancer.
Avril N; Sassen S; Roylance R
J Nucl Med; 2009 May; 50 Suppl 1():55S-63S. PubMed ID: 19380410
[TBL] [Abstract][Full Text] [Related]
25. Role of positron emission tomography for the monitoring of response to therapy in breast cancer.
Humbert O; Cochet A; Coudert B; Berriolo-Riedinger A; Kanoun S; Brunotte F; Fumoleau P
Oncologist; 2015 Feb; 20(2):94-104. PubMed ID: 25561512
[TBL] [Abstract][Full Text] [Related]
26. Prognostic significance of pretreatment
Han S; Lee SB; Gong G; Lee J; Chae SY; Oh JS; Moon DH
Breast Cancer Res Treat; 2023 Apr; 198(2):207-215. PubMed ID: 36633721
[TBL] [Abstract][Full Text] [Related]
27. Metabolic Positron Emission Tomography in Breast Cancer.
Cecil K; Huppert L; Mukhtar R; Dibble EH; O'Brien SR; Ulaner GA; Lawhn-Heath C
PET Clin; 2023 Oct; 18(4):473-485. PubMed ID: 37369614
[TBL] [Abstract][Full Text] [Related]
28. GlucoCEST MRI for the Evaluation Response to Chemotherapeutic and Metabolic Treatments in a Murine Triple-Negative Breast Cancer: A Comparison with[
Capozza M; Anemone A; Dhakan C; Della Peruta M; Bracesco M; Zullino S; Villano D; Terreno E; Longo DL; Aime S
Mol Imaging Biol; 2022 Feb; 24(1):126-134. PubMed ID: 34383241
[TBL] [Abstract][Full Text] [Related]
29. Head-to-Head Evaluation of
Ulaner GA; Jhaveri K; Chandarlapaty S; Hatzoglou V; Riedl CC; Lewis JS; Mauguen A
J Nucl Med; 2021 Mar; 62(3):326-331. PubMed ID: 32680923
[TBL] [Abstract][Full Text] [Related]
30. Higher breast cancer conspicuity on dbPET compared to WB-PET/CT.
Nishimatsu K; Nakamoto Y; Miyake KK; Ishimori T; Kanao S; Toi M; Togashi K
Eur J Radiol; 2017 May; 90():138-145. PubMed ID: 28583624
[TBL] [Abstract][Full Text] [Related]
31. Phase II Trial Assessing the Repeatability and Tumor Uptake of [
Gondry O; Caveliers V; Xavier C; Raes L; Vanhoeij M; Verfaillie G; Fontaine C; Glorieus K; De Grève J; Joris S; Luyten I; Zwaenepoel K; Vandenbroucke F; Waelput W; Thyparambil S; Vaneycken I; Cousaert J; Bourgeois S; Devoogdt N; Goethals L; Everaert H; De Geeter F; Lahoutte T; Keyaerts M
J Nucl Med; 2024 Feb; 65(2):178-184. PubMed ID: 38302159
[TBL] [Abstract][Full Text] [Related]
32. FDG-PET/CT detection of very early breast cancer in women with breast microcalcification lesions found in mammography screening.
Peng NJ; Chou CP; Pan HB; Chang TH; Hu C; Chiu YL; Fu TY; Chang HT
J Med Imaging Radiat Oncol; 2015 Aug; 59(4):445-452. PubMed ID: 25872026
[TBL] [Abstract][Full Text] [Related]
33. Does whole-body Patlak
Fahrni G; Karakatsanis NA; Di Domenicantonio G; Garibotto V; Zaidi H
Eur Radiol; 2019 Sep; 29(9):4812-4821. PubMed ID: 30689031
[TBL] [Abstract][Full Text] [Related]
34. Role of dynamic and parametric whole-body FDG PET/CT imaging in molecular characterization of primary breast cancer: a single institution experience.
Sundaraiya S; T R; Nangia S; Sirohi B; Patil S
Nucl Med Commun; 2022 Sep; 43(9):1015-1025. PubMed ID: 35950356
[TBL] [Abstract][Full Text] [Related]
35. PET Imaging of Breast Cancer: Role in Patient Management.
Lebron L; Greenspan D; Pandit-Taskar N
PET Clin; 2015 Apr; 10(2):159-95. PubMed ID: 25829085
[TBL] [Abstract][Full Text] [Related]
36. 18F-Deoxyglucose (18F-FDG) Positron Emission Tomography/Computed Tomography (PET/CT) Monitoring of Dynamic Growth Characteristics of Walker-256 Tumor Models in 3 Different Locations in Rats.
Li P; Liu Q; Wang X; Huang G; Song S
Med Sci Monit; 2019 Jan; 25():558-564. PubMed ID: 30659557
[TBL] [Abstract][Full Text] [Related]
37. Intratumoral heterogeneity in
Molina-García D; García-Vicente AM; Pérez-Beteta J; Amo-Salas M; Martínez-González A; Tello-Galán MJ; Soriano-Castrejón Á; Pérez-García VM
Ann Nucl Med; 2018 Jul; 32(6):379-388. PubMed ID: 29869770
[TBL] [Abstract][Full Text] [Related]
38.
Gebhart G
J Nucl Med; 2023 Nov; 64(11):1697-1698. PubMed ID: 37918851
[No Abstract] [Full Text] [Related]
39. Application of PET Tracers in Molecular Imaging for Breast Cancer.
Boers J; de Vries EFJ; Glaudemans AWJM; Hospers GAP; Schröder CP
Curr Oncol Rep; 2020 Jul; 22(8):85. PubMed ID: 32627087
[TBL] [Abstract][Full Text] [Related]
40. Estrogen Receptor Binding (18F-FES PET) and Glycolytic Activity (18F-FDG PET) Predict Progression-Free Survival on Endocrine Therapy in Patients with ER+ Breast Cancer.
Kurland BF; Peterson LM; Lee JH; Schubert EK; Currin ER; Link JM; Krohn KA; Mankoff DA; Linden HM
Clin Cancer Res; 2017 Jan; 23(2):407-415. PubMed ID: 27342400
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
